NCT00174421
Completed
Phase 3
Genotropin in Short Children Born Small for Gestational Ag - A Long-Term Study in Belgium
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Growth Disorder
- Sponsor
- Pfizer
- Enrollment
- 36
- Primary Endpoint
- Final height, compared to the expected familial target height
- Status
- Completed
- Last Updated
- 19 years ago
Overview
Brief Summary
This trial evaluates whether long-term treatment with Genotropin normalizes final (adult) height in short children born small for gestational age
Investigators
Eligibility Criteria
Inclusion Criteria
- •Participation in the 90-080 study
Exclusion Criteria
- •Any severe, acute or chronic disease
- •Any other identifiable reason for short stature
Outcomes
Primary Outcomes
Final height, compared to the expected familial target height
Secondary Outcomes
- Body weight, body mass index at final height; adverse events and assessment of hematological and clinical chemistry
Similar Trials
Completed
Phase 3
Treatment Of Children With Short Stature At An Age Of 3-7 Years Who Were Born Small For Gestational AgeGrowth DisordersNCT00174408Pfizer110
Completed
Phase 4
Long Term Study of Genotropin (Somatropin) for Short Children Born Small for Gestational Age (SGA)Short Stature Born Small for Gestational Age (SGA)NCT01859949Pfizer62
Completed
Phase 2
Growth Response in Short Children Suffering From a Disease With Growth Retardation and Treated With SomatropinIdiopathic Short StatureNCT00488124University of Erlangen-Nürnberg Medical School120
Completed
Phase 3
Genotropin Treatment in Short Prepubertal Children With Intra-Uterine Growth RetardationGrowth DisordersIntrauterine Growth RetardationNCT01073605Pfizer208
Terminated
Phase 2
Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's DiseaseArthritis, Juvenile RheumatoidCrohn DiseaseNCT00511329Nationwide Children's Hospital10